"Recombinant Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins prepared by recombinant DNA technology.
| Descriptor ID |
D011994
|
| MeSH Number(s) |
D12.776.828
|
| Concept/Terms |
Recombinant Proteins- Recombinant Proteins
- Proteins, Recombinant
- Proteins, Biosynthetic
- Biosynthetic Proteins
Proteins, Recombinant DNA- Proteins, Recombinant DNA
- DNA Proteins, Recombinant
- Recombinant DNA Proteins
- DNA Recombinant Proteins
- Proteins, DNA Recombinant
- Recombinant Proteins, DNA
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Proteins".
This graph shows the total number of publications written about "Recombinant Proteins" by people in this website by year, and whether "Recombinant Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 5 | 5 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Proteins" by people in Profiles.
-
Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018 01; 16(1):39-43.
-
Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors. Haemophilia. 2017 Nov; 23(6):844-851.
-
PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding. Haemophilia. 2017 Nov; 23(6):832-843.
-
Wnt5a induces catabolic signaling and matrix metalloproteinase production in human articular chondrocytes. Osteoarthritis Cartilage. 2017 09; 25(9):1505-1515.
-
Bone Morphogenetic Proteins in Lumbar Arthrodesis: What Is All the Debate About? Commentary on an article by Daniel C. Beachler, PhD, MHS, et al.: "Bone Morphogenetic Protein Use and Cancer Risk Among Patients Undergoing Lumbar Arthrodesis: A Case-Cohort Study Using the SEER-Medicare Database". J Bone Joint Surg Am. 2016 07 06; 98(13):e57.
-
Delivering heparin-binding insulin-like growth factor 1 with self-assembling peptide hydrogels. Tissue Eng Part A. 2015 Feb; 21(3-4):637-46.
-
Combined use of low-intensity pulsed ultrasound and rhBMP-2 to enhance bone formation in a rat model of critical size defect. J Orthop Trauma. 2014 Oct; 28(10):605-11.
-
Intravenous thrombolysis for ischemic stroke in recurrent oligodendroglioma: a case report. J Stroke Cerebrovasc Dis. 2014 May-Jun; 23(5):1235-8.
-
Systemically delivered insulin-like growth factor-I enhances mesenchymal stem cell-dependent fracture healing. Growth Factors. 2012 Aug; 30(4):230-41.
-
Healing of rat femoral segmental defect with bone morphogenetic protein-2: a dose response study. J Musculoskelet Neuronal Interact. 2012 Mar; 12(1):28-37.